cerebral small vessel disease
Conditions
Interventions
experience group:N/A
Healthy control group:N/A
Sponsors
Jincheng people's Hospital Affiliated to Shanxi Medical University
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. CSVD participants who meet the criteria of STRIVE(Standards for reporting vascular changes on neuroimaging) and are aged 50-85 years will be enrolled in the present study. MRI brain scans show multiple white matter disease. 2. No history of central nervous system diseases such as head trauma, encephalitis, epilepsy, Parkinson's disease, Alzheimer's disease, frontotemporal dementia, and Huntington's disease. No patients had systemic diseases causing cognitive impairment. 3. There are no diseases that affect neuropsychological examination, including severe impairment of hearing and vision, aphasia and dominant hemiplegia. 4. No history of mental illness such as congenital mental retardation or anxiety and depression(HAMD < 7, HAMA< 7, excluding anxiety, depression and cognitive impairment caused by specific reasons). 5. Not taking drugs that affect cognitive function. 6. There are no metal objects in the body, and the patient can cooperate to complete magnetic resonance imaging (MRI) examination. 7. Patients can cooperate to complete the evaluation of cognitive function, including Mini-Mental State examination(MMSE) and Montreal Cognitive Assessment (MoCA). 8. All patients need to sign the informed consent. The inclusion criteria of the control group: 1. Age 50-80; 2. There are no metal objects in the body, which can be used to complete the magnetic resonance examination; 3. No MRI findings related to cerebrovascular disease, including white matter hyperintensity, micro hemorrhage, perivascular space, lacuna and brain atrophy; 4. Inform the patients and their families of this study. The patients and their families are willing to cooperate with relevant examinations and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Head MRI show small vascular diseases other than WMH, such as resting infarction or microbleeding; 2. Brain MRI clearly indicates atrophy of cortex or hippocampus; 3. Hachiski ischemia scale suggests that cognitive impairment may be caused by degenerative diseases; 4. Alcohol or drug dependence; 5. Conscious disorders, aphasia and other diseases that affect cognitive evaluation. Exclusion criteria for the control group: 1. Head injury, encephalitis, epilepsy, Parkinson's disease, Alzheimer's disease, frontotemporal dementia, schizophrenia and other neurological or psychiatric diseases; 2. Severe liver and kidney dysfunction or other systemic diseases; 3. Alcohol or drug dependence; 4. Those who cannot perform the clinical evaluation (such as those who cannot cooperate due to blindness, hearing impairment, aphasia, severe dementia and other reasons).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| White matter lesion volume of CSVD;Serum AngII, Ang (1-7) levels and AngII/Ang(1-7) ratio;Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA); | — |
Countries
China
Contacts
Public ContactHongjiang Cheng
Jincheng people's Hospital Affiliated to Shanxi Medical University
Outcome results
None listed